This has been recently investigated clinically in a phase II, non-randomized study of 38 treatment-naive patients with advanced nonsquamous NSCLC, no EGFR, STIK11, MDM2, or ROS1 mutations, and a tumor mutational burden (TMB) > 10 mutations/megabase who received bevacizumab + atezolizumab. This evidence concerns the gene EGFR and neoplasm.